je.st
news
Tag: pharmaceuticals
BioCryst Pharmaceuticals Price Target Lowered to $10.00 at Jefferies Group
2015-10-18 09:44:56| Biotech - Topix.net
The firm presently has a "hold" rating on the biotechnology company's stock. Jefferies Group's price objective would indicate a potential upside of 13.12% from the stock's previous close.
Tags: price
group
target
lowered
AstraZeneca and Peregrine Pharmaceuticals Expand Ongoing...
2015-10-15 23:17:26| Biotech - Topix.net
Peregrine Pharmaceuticals, Inc. , a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that it has expanded its ongoing cancer immunotherapy clinical collaboration with AstraZeneca to include a second, later-stage trial. The companies will now also evaluate the immunotherapy combination of Peregrine's phosphatidylserine -targeted immune-activator, bavituximab, and AstraZeneca's anti-PD-L1 immune checkpoint inhibitor, durvalumab , in a global Phase II study in patients with previously treated squamous or non-squamous non-small cell lung cancer .
Tags: expand
ongoing
pharmaceuticals
peregrine
Regeneron Pharmaceuticals Rating Reiterated by Piper Jaffray
2015-10-04 23:23:38| Biotech - Topix.net
's stock had its "hold" rating restated by stock analysts at Piper Jaffray in a research report issued to clients and investors on Sunday, Analyst Ratings.Net reports. Shares of Regeneron Pharmaceuticals traded up 1.29% during trading on Friday, reaching $479.07.
Tags: rating
pharmaceuticals
piper
jaffray
OncoRx Pharmaceuticals Inc. Announces Treatments For Therapy-Resistant Tumors
2015-09-30 09:09:13| drugdiscoveryonline News Articles
OncoRx Pharmaceuticals, Inc. is announcing its launch as an early-stage pharmaceutical company focused on the development of drug therapies that control the progression of therapy-resistant malignant tumors
Tags: treatments
announces
pharmaceuticals
tumors
Regeneron Pharmaceuticals major shareholder Sanofi Acquires 147,209 Shares
2015-09-27 09:48:03| Apparel - Topix.net
Regeneron Pharmaceuticals major shareholder Sanofi bought 147,209 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, September 23rd. The shares were bought at an average cost of $534.67 per share, with a total value of $78,708,236.03.
Tags: major
shares
shareholder
pharmaceuticals
Sites : [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] next »